407 related articles for article (PubMed ID: 25210173)
1. Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene.
Kamlangdee A; Kingstad-Bakke B; Anderson TK; Goldberg TL; Osorio JE
J Virol; 2014 Nov; 88(22):13300-9. PubMed ID: 25210173
[TBL] [Abstract][Full Text] [Related]
2. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
Kamlangdee A; Kingstad-Bakke B; Osorio JE
J Virol; 2016 Aug; 90(15):6771-6783. PubMed ID: 27194759
[TBL] [Abstract][Full Text] [Related]
3. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.
Florek KR; Weinfurter JT; Jegaskanda S; Brewoo JN; Powell TD; Young GR; Das SC; Hatta M; Broman KW; Hungnes O; Dudman SG; Kawaoka Y; Kent SJ; Stinchcomb DT; Osorio JE; Friedrich TC
J Virol; 2014 Nov; 88(22):13418-28. PubMed ID: 25210172
[TBL] [Abstract][Full Text] [Related]
4. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
[TBL] [Abstract][Full Text] [Related]
5. Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge.
Kingstad-Bakke B; Kamlangdee A; Osorio JE
Vaccine; 2015 Sep; 33(39):5155-62. PubMed ID: 26271828
[TBL] [Abstract][Full Text] [Related]
6. Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice.
He F; Prabakaran M; Rajesh Kumar S; Tan Y; Kwang J
Antiviral Res; 2014 May; 105():143-51. PubMed ID: 24637255
[TBL] [Abstract][Full Text] [Related]
7. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.
Mayrhofer J; Coulibaly S; Hessel A; Holzer GW; Schwendinger M; Brühl P; Gerencer M; Crowe BA; Shuo S; Hong W; Tan YJ; Dietrich B; Sabarth N; Savidis-Dacho H; Kistner O; Barrett PN; Falkner FG
J Virol; 2009 May; 83(10):5192-203. PubMed ID: 19279103
[TBL] [Abstract][Full Text] [Related]
8. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
[TBL] [Abstract][Full Text] [Related]
9. Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.
Brewoo JN; Powell TD; Jones JC; Gundlach NA; Young GR; Chu H; Das SC; Partidos CD; Stinchcomb DT; Osorio JE
Vaccine; 2013 Apr; 31(14):1848-55. PubMed ID: 23376279
[TBL] [Abstract][Full Text] [Related]
10. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
11. Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial.
de Vries RD; Altenburg AF; Nieuwkoop NJ; de Bruin E; van Trierum SE; Pronk MR; Lamers MM; Richard M; Nieuwenhuijse DF; Koopmans MPG; Kreijtz JHCM; Fouchier RAM; Osterhaus ADME; Sutter G; Rimmelzwaan GF
J Infect Dis; 2018 Jul; 218(4):614-623. PubMed ID: 29912453
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
[TBL] [Abstract][Full Text] [Related]
13. A modified vaccinia Ankara vaccine vector expressing a mosaic H5 hemagglutinin reduces viral shedding in rhesus macaques.
Florek KR; Kamlangdee A; Mutschler JP; Kingstad-Bakke B; Schultz-Darken N; Broman KW; Osorio JE; Friedrich TC
PLoS One; 2017; 12(8):e0181738. PubMed ID: 28771513
[TBL] [Abstract][Full Text] [Related]
14. Progress toward a universal H5N1 vaccine: a recombinant modified vaccinia virus Ankara-expressing trivalent hemagglutinin vaccine.
Prabakaran M; Leyrer S; He F; Auer S; Kumar SR; Kindsmueller K; Mytle N; Schneider J; Lockhart S; Kwang J
PLoS One; 2014; 9(9):e107316. PubMed ID: 25229722
[TBL] [Abstract][Full Text] [Related]
15. Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.
Mooney AJ; Li Z; Gabbard JD; He B; Tompkins SM
J Virol; 2013 Jan; 87(1):363-71. PubMed ID: 23077318
[TBL] [Abstract][Full Text] [Related]
16. Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice.
Kim EH; Park HJ; Han GY; Song MK; Pereboev A; Hong JS; Chang J; Byun YH; Seong BL; Nguyen HH
J Virol; 2014 Sep; 88(17):9693-703. PubMed ID: 24920793
[TBL] [Abstract][Full Text] [Related]
17. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response.
Lee JS; Chowdhury MY; Moon HJ; Choi YK; Talactac MR; Kim JH; Park ME; Son HY; Shin KS; Kim CJ
J Virol Methods; 2013 Dec; 194(1-2):280-8. PubMed ID: 24004822
[TBL] [Abstract][Full Text] [Related]
18. Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses.
Li H; Sun H; Tao M; Han Q; Yu H; Li J; Lu X; Tong Q; Pu J; Sun Y; Liu L; Liu J; Sun H
J Virol; 2024 Mar; 98(3):e0112923. PubMed ID: 38305155
[TBL] [Abstract][Full Text] [Related]
19. Effective mosaic-based nanovaccines against avian influenza in poultry.
Kingstad-Bakke BA; Chandrasekar SS; Phanse Y; Ross KA; Hatta M; Suresh M; Kawaoka Y; Osorio JE; Narasimhan B; Talaat AM
Vaccine; 2019 Aug; 37(35):5051-5058. PubMed ID: 31300285
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
